Table I-5, Pharmacologic agents considered for DBD review - Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Epstein R, Fonnesbeck C, Williamson E, et al. Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Oct. (Comparative Effectiveness Reviews, No. 154.)

Cover of Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents

Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents [Internet].

Show details

Contents

Table I-5Pharmacologic agents considered for DBD review

Drug Class Individual agent (proprietary name)
Alpha-agonists Clonidine Guanfacine (Intuniv®)	First-generation antipsychotics Chlorpromazine Fluphenazine Haloperidol Loxapine Perphenazine Prochlorperazine Thiothixene Thioridazine Trifluoperazine	Selective serotonin reuptake inhibitors (SSRI) Fluoxetine Sertraline Citalopram Escitalopram Paroxetine Fluvoxamine
Anticonvulsants Carbamazepine (Tegretol®) Oxcarbazepine (Trileptal®) Divalproex sodium (Depakote®) Lamotrigine (Lamictal®) Valproate/ Valproic acid
Beta-blockers Propranolol Metoprolol Pindolol Nadolol	Second-generation (atypical) antipsychotics Aripiprazole (Abilify®) Asenapine (Saphris®) Clozapine (Clozaril®) Iloperidone (Fanapt®) Lurasidone (Latuda®) Olanzapine (Zyprexa®) Olanzapine/Fluoxetine (Symbyax®) Paliperidone (Invega®) Quetiapine (Seroquel®) Risperidone (Risperdal®) Ziprasidone (Geodon®)	Other (e.g., antihistamines, benzodiazepines, mood stabilizers, non-SSRI antidepressants) Lithium Atomoxetine (Strattera®) Naltrexone Hydroxyzine Clonazepam (Klonopin®) Levetiracetam (Keppra®) Lorazepam (Ativan®) Bupropion
Central nervous system (CNS) stimulants Amphetamine-Dextroamphetamine (Adderall®) Methylphenidate (Ritalin®) Lisdexamfetamine (Vyvanse®)

From: Appendix I, Pharmacologic Approval Status, Harms, and Indications

Contents

Views

Cite this Page
Epstein R, Fonnesbeck C, Williamson E, et al. Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Oct. (Comparative Effectiveness Reviews, No. 154.) Table I-5, Pharmacologic agents considered for DBD review.
PDF version of this title (3.0M)

Other titles in these collections

Recent Activity

Clear Turn Off Turn On

Table I-5, Pharmacologic agents considered for DBD review - Psychosocial and Pha...
Table I-5, Pharmacologic agents considered for DBD review - Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on